J&J to boost medical device division with acquisition

Johnson & Johnson (J&J) has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.

The multinational medical device and pharmaceutical company announced its acquisition plans on Tuesday, February 20.

Orthotaxy designs and develops computer-assisted platforms and owns proprietary software-enabled surgery technologies.

The acquisition underscores J&J’s “commitment in building an innovative and comprehensive digital surgery platform”, according to the release.

J&J, which will acquire Orthotaxy through French affiliate Apsis, plans to broaden the application of Orthotaxy’s robotic-assisted surgery technology, which is currently in early stage development for knee replacements, to include a range of orthopaedic surgery procedures.

Ciro Rӧmer, chairman of J&J’s orthopaedics business DePuy Synthes, said: “Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers.”

He added that the acquisition will enable J&J to bring a “differentiated technology” to market, improving clinical outcomes and patient satisfaction.

Last year, J&J Innovation, the division that focuses on forming collaborations between entrepreneurs and J&J’s healthcare businesses, announced a series of new collaborations, as reported by LSIPR.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.